Carlyle Group’s Jasper Therapeutics JSPR Stock Holding History

Carlyle Group’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$934K	Hold	1,066,189	–	–	0.01%	14
2025 Q4	$1.94M	Hold	1,066,189	–	–	0.01%	11
2025 Q3	$2.53M	Hold	1,066,189	–	–	0.06%	9
2025 Q2	$5.92M	Hold	1,066,189	–	–	0.12%	8
2025 Q1	$4.58M	Hold	1,066,189	–	–	0.12%	11
2024 Q4	$22.7M	Hold	1,066,189	–	–	0.55%	6
2024 Q3	$19.9M	Hold	1,066,189	–	–	2.08%	7
2024 Q2	$24.2M	Hold	1,066,189	–	–	2.3%	9
2024 Q1	$31.3M	Buy	1,066,189 +190,000	+22%	+$3.37M	1.97%	8
2023 Q4	$6.67M	Hold	876,189	–	–	0.32%	15
2023 Q3	$6.05M	Hold	876,189	–	–	0.26%	17
2023 Q2	$11.8M	Hold	876,189	–	–	0.42%	14
2023 Q1	$15.8M	Buy	+876,189	New	+$16.2M	0.47%	12

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Carlyle Group's JSPR Position: Q1 2026 in Review

Carlyle Group held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 1,066,189 shares worth $934K. The position accounts for 0.01% of the portfolio, ranked #14.

Carlyle Group first reported a position in JSPR in Q1 2023 and has held it in 13 quarters since. The position peaked at $31.3M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Carlyle Group held 1,066,189 shares of Jasper Therapeutics worth $934K as of Q1 2026.
Carlyle Group left its Jasper Therapeutics share count unchanged in Q1 2026.
Jasper Therapeutics made up 0.01% of Carlyle Group's portfolio in Q1 2026, its #14 holding.
Carlyle Group first reported a position in Jasper Therapeutics in Q1 2023 and has held it in 13 quarters since.
Carlyle Group's Jasper Therapeutics position peaked at $31.3M in Q1 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Carlyle Group's 13F filing for Q1 2026, filed 8 May 2026.